NCT06012097 Impact of Gel Aromatherapy on Pain for Patients With De Quervain Disease

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.

This trial targets 70 participants in total. It began in 2024-06-04 with a primary completion date of 2026-04-01.

Brief Summary

De Quervain disease is characterized by an adductor pollicis longus and extensor pollicis brevis tendons inflammation as thys pass beneath the extensor retinaculum at the radial styloid. This pathology is recognized as a musculoskeletal disorder of the upper limb triggering functional deficits resulting to possible modifications in the professional activity, sources of absenteeism, thus constituting an economic cost for society. At the etiological level, this pathology also affects young mothers (it's called "mother's wrist" or mommy thumb"), mobile phone users ("textonite", "Blackberryte") or video game players ("Nintendoite"). Currently, the treatment is mainly conservative by splint and anti-inflammatory gel and/or corticosteroid infiltration. Howewer, these therapies have undesirable effects. The interest of this study is therefore to propose another therapy based on aromatherapy gel.

Eligibility Criteria

Inclusion Criteria: * Male or female patient aged 18 to 75, * Patient with unilateral De Quervain's tenosynovitis, * Patient cared in the Hand Surgery Department, SOS Mains Emergency Department or Rheumatology Department of Strasbourg University Hospitals, * Patient informed of the results of the prior medical examination, * Informed consent signed by the patient, * Patient affiliated to a health insurance social protection scheme or beneficiary, * For a woman of childbearing potential, negative urine pregnancy test at the inclusion visit and maintenance of effective contraception throughout the study. Exclusion Criteria: * Pregnant or breastfeeding patient, * Patient allergic to a component of the gel with essential oils, Dicloflenac®, NSAIDs, or one of the excipients * Patient treated with oral non-steroidal anti-inflammatory drugs * Patient with ongoing treatment with another ointment at the treatment application site (radial edge of the wrist) * Patient with damaged skin, whatever the lesion: oozing dermatosis, eczema, infected lesion, burn or wound, * Patient with atopic skin disease, * Patient with epilepsy or with a history of epilepsy, * Patient with a history of homolateral De Quervain's tenosynovitis, or having already had corticosteroid infiltrations in the 6 months before his inclusion on the ipsilateral side of the pathology, * Patient with associated tendinopathies in the elbow or forearm region, * Impossibility of giving the patient information (patient in an emergency situation, patient with difficulties of understandin, agitation of the patient), * Patient under legal protection, under guardianship or curatorship.

Contact & Investigator

Frequently Asked Questions

Related Trials